Latvija - latviešu - Zāļu valsts aģentūra

besins healthcare ireland limited, ireland - progesterons - vaginālā kapsula, mīkstā - 300 mg

Latvija - latviešu - Zāļu valsts aģentūra

sandoz d.d., slovenia - paracetamolum, phenylephrini hydrochloridum - pulveris iekšķīgi lietojama šķīduma pagatavošanai - 500 mg/12,2 mg

Latvija - latviešu - Zāļu valsts aģentūra

sandoz d.d., slovenia - paracetamolum, phenylephrini hydrochloridum - pulveris iekšķīgi lietojama šķīduma pagatavošanai - 1000 mg/12,2 mg

Latvija - latviešu - Zāļu valsts aģentūra

mcneil healthcare (ireland) limited, ireland - ksilometazolīna hidrohlorīds - deguna aerosols, šķīdums - 1 mg/ml

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

accord healthcare s.l.u. - rivaroxaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - antitrombotiskie līdzekļi - venozās trombembolijas (vte) profilakse pieaugušiem pacientiem, kuriem tiek veikta gēnu vai ceļa locītavas locītavas operācija. Ārstēšana ar dziļo vēnu tromboze (dvt) un plaušu embolija (pe), un novērst atkārtotu dvt un pe pieaugušajiem. (see section 4. 4 for haemodynamically unstable pe patients. Ārstēšana ar dziļo vēnu tromboze (dvt) un plaušu embolija (pe), un novērst atkārtotu dvt un pe pieaugušajiem. (see section 4. 4 haemodynamically nestabila pe pacientiem). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. Ārstēšana ar dziļo vēnu tromboze (dvt) un plaušu embolija (pe), un novērst atkārtotu dvt un pe pieaugušajiem. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 un 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. Ārstēšana ar dziļo vēnu tromboze (dvt) un plaušu embolija (pe), un novērst atkārtotu dvt un pe pieaugušajiem. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

novartis europharm limited - omalizumab - asthma; urticaria - zāles obstruktīvu elpceļu slimību, - alerģiskas asthmaxolair ir norādīts pieaugušajiem, pusaudžiem un bērniem (no 6 līdz.

Latvija - latviešu - Zāļu valsts aģentūra

mcneil healthcare (ireland) limited, ireland - xylometazolini hydrochloridum, dexpanthenolum - deguna aerosols, šķīdums - 1 mg/50 mg/ml

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

laboratoire francais du fractionnement et des biotechnologies - eptacog beta (activated) - hemophilia a; hemophilia b - antihemorāģija - cevenfacta is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with high-responding inhibitors to coagulation factors viii or ix (i. ≥5 bethesda units (bu)); in patients with congenital haemophilia with low titre inhibitors (bu.

Latvija - latviešu - Zāļu valsts aģentūra

richard bittner ag, austria - paracetamolum, phenylephrini hydrochloridum, skābes ascorbicum - pulveris iekšķīgi lietojama šķīduma pagatavošanai paciņā - 300 mg/5 mg/20 mg

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

bayer ag - rivaroxaban - arthroplasty, replacement; venous thromboembolism - antitrombotiskie līdzekļi - xarelto, co-ievadīts ar acetilsalicilskābi (asa) atsevišķi vai kopā ar asa plus klopidogrelu vai ticlopidine, ir norādīts, lai novērstu atherothrombotic notikumiem pieaugušiem pacientiem pēc akūta koronāra sindroma (acs) ar paaugstinātu sirds izmeklējumus. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. venozās trombembolijas (vte) profilakse pieaugušiem pacientiem, kuriem tiek veikta gēnu vai ceļa locītavas locītavas operācija. Ārstēšana ar dziļo vēnu tromboze (dvt) un plaušu embolija (pe), un novērst atkārtotu dvt un pe pieaugušajiem. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.